MSD (organization)

MSD (organization). MSD, known as Merck & Co. in the United States and Canada, is a leading global biopharmaceutical company headquartered in Kenilworth, New Jersey. It discovers, develops, manufactures, and markets a broad range of human and animal health products, with a significant historical legacy in infectious disease and vaccinology. The company operates as a separate entity from the German Merck Group, which retains rights to the Merck name in most other regions.

History

The organization traces its origins to 1891 when George Merck, a descendant of the founder of the German Merck Group, established an American subsidiary in New York City. The U.S. operation was seized as enemy property during World War I and became an independent American company in 1917. A pivotal moment came in 1933 with a research partnership with Selman Waksman of Rutgers University, leading to the discovery of streptomycin, the first effective treatment for tuberculosis. Throughout the 20th century, MSD expanded globally, establishing major research facilities like the Merck Sharp & Dohme Research Laboratories and introducing landmark products including the first measles vaccine and early cholesterol-lowering agents.

Operations and products

MSD's commercial operations are divided into two primary segments: human health and animal health. Its human health portfolio includes major therapeutic areas such as oncology, vaccines, infectious diseases, and cardiology. Key blockbuster products include the HPV vaccine Gardasil, the PD-1 inhibitor Keytruda for various cancers, and the antiviral drug Lagevrio for COVID-19. The animal health division, known as Merck Animal Health, develops veterinary pharmaceuticals, vaccines, and health management products for livestock and companion animals. The company maintains a vast global supply chain with manufacturing plants across the Americas, Europe, and Asia.

Corporate affairs

MSD is a publicly traded company listed on the New York Stock Exchange under the ticker symbol MRK. Its corporate governance is led by a Board of directors and Robert M. Davis, who serves as Chairman and CEO. The company maintains a significant philanthropic presence through the Merck Foundation, which focuses on improving health and wellbeing worldwide. MSD has engaged in numerous strategic collaborations and acquisitions, such as the purchase of Schering-Plough in 2009 and Acceleron Pharma in 2021, to bolster its research pipeline and market reach.

Research and development

MSD invests heavily in R&D, with expenditures consistently exceeding $10 billion annually. Its discovery efforts are centered at major research laboratories in West Point, Pennsylvania, Boston, and Cambridge, UK, among other global sites. The R&D strategy focuses on key areas including immuno-oncology, infectious diseases like HIV and hepatitis C, and cardiometabolic disease. The company has a strong legacy in vaccine development, with ongoing research into vaccines for Ebola, Dengue fever, and other global health threats. Collaborations with academic institutions like the University of Oxford and biotech firms are a cornerstone of its innovation model.

Controversies and legal issues

The organization has faced significant legal and ethical challenges. It was involved in major litigation concerning the safety of its COX-2 inhibitor Vioxx, which was withdrawn from the market in 2004 after being linked to increased heart attack risk. MSD has also faced scrutiny over the marketing practices for several drugs, leading to settlements with the U.S. Department of Justice under the False Claims Act. More recently, the company has engaged in patent disputes and pricing debates related to Keytruda and Gardasil. Environmental concerns, including allegations of pollution from manufacturing sites, have also resulted in regulatory actions and settlements.

Category:Pharmaceutical companies of the United States Category:Companies listed on the New York Stock Exchange Category:Companies based in New Jersey